The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria: * male or female (postmenopausal, surgically sterile or using double-barrier method of contraception) healthy subjects and patients with type 2 diabetes mellitus (T2DM) * must be able to complete a 1 week wash-out of current anti-diabetic medications * Age 30-70 years * HbA1c (Hemoglobin A1c) ≤11% at screening * Body mass index (BMI) \<40 kg/m2 * Patients with type 2 diabetes mellitus (T2DM): Must have a fasting blood glucose of ≤12.2 mmol/L (240 mg/dL) at screening * Able to provide written informed consent prior to study participation * Able to communicate well with the investigator and comply with the requirements of the study Exclusion Criteria: * Patients with type 1 diabetes mellitus (T1DM), diabetes as a result of pancreatic injury, or secondary forms of diabetes (eg Cushing, acromegaly) * Need for insulin within the previous 3 months * Use of Thiazolidinediones in the previous 4 weeks * Significant concomitant disease or complications of diabetes (i.e. nephropathy, autonomic dysfunction, orthostasis). * Treatment with systemic steroids and thyroid hormone (unstable dosage). * Patients with any history of gastrointestinal surgery, e.g. partial bowel resections, partial gastric resections, etc. * Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. * Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing. * Significant illness within the two weeks prior to dosing.…